If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

Share Price is delayed by 15 minutes
Get Live Data
6.35    0.15 (2.42%)
Bid:
6.20
Ask:
6.50
Spread: 0.30 (4.839%)
Market Cap: £67.91m
STX Live PriceLast checked at - London Stock Exchange

Intraday Shield Thera Share Chart

Form 8.5 (EPT/RI) - Shield Therapeutics Plc

25 May 2023 12:00

RNS Number : 6702A
Peel Hunt LLP
25 May 2023
Β 

FORM 8.5 (EPT/RI)

Β 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

Β 

1. KEY INFORMATION

Β 

(a) Name of exempt principal trader:

Peel Hunt LLP

(b) Name of offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Shield Therapeutics Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Shield Therapeutics Plc

(d) Date dealing undertaken:

24 May 2023

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

Β 

N/A

Β 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Β 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

Β 

(a) Purchases and sales

Β 

Class of relevant security

Purchases/ sales

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Ordinary Shares

Purchase

23,255

6.80 GBx

6.80 GBx

Ordinary Shares

Sale

132,498

6.92 GBx

6.89 GBx

Β 

Β (b) Cash-settled derivative transactions

Β 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

Β 

(c) Stock-settled derivative transactions (including options)

Β 

(i) Writing, selling, purchasing or varying

Β 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

Β 

(ii) Exercise

Β 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

Β 

Β 

Β 

Β 

Β 

Β 

(d) Other dealings (including subscribing for new securities)

Β 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

Β 

Β 

Β 

Β 

Β 

3. OTHER INFORMATION

Β 

(a) Indemnity and other dealing arrangements

Β 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

Β 

None

Β 

Β 

(b) Agreements, arrangements or understandings relating to options or derivatives

Β 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

Β 

If there are no such agreements, arrangements or understandings, state "none"

Β 

None

Β 

Date of disclosure:

25 May 2023

Β 

Contact name:

Alexandra Forner

Telephone number:

0207 847 4740

Β 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

Β 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
FERBGGDUUBDDGXU
Date   Source Headline
6th Jan 20177:00 amRNSBusiness Update
7th Nov 20167:00 amRNSBoard Change
20th Sep 20167:00 amRNSInterim Results for six months ended 30 June 2016
13th Sep 20169:25 amRNSGrant of Share Awards
7th Sep 20167:37 amRNSComposition of Matter Patent Granted on Feraccru®
7th Sep 20167:00 amRNSComposition of Matter Patent Granted on Feraccru®
15th Aug 201612:22 pmRNSNotice of Results
4th Aug 201611:05 amRNSResult of AGM
1st Aug 201612:00 pmRNSPresenting at Canaccord Genuity Conference, Boston
30th Jun 20165:06 pmRNS2015 Annual Report and Accounts and Notice of AGM
14th Jun 20167:00 amRNSMaiden Preliminary Results for FY15
23rd Mar 20167:00 amRNSNotice of results and change of accounting date
11th Mar 20167:00 amRNSGrant of Share Awards
26th Feb 20168:34 amRNSFirst Day of Dealings on AIM
26th Feb 20167:00 amRNSFeraccru® receives EU marketing authorisation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.